08 Jul 2021
Posted in Pharma
Huntington’s disease market is forecast to reach $918m by 2030 in the 3MM
The Huntington’s disease (HD) market is projected to grow at a Compound Annual Growth Rate (CAGR) of 13.8%, reaching $917.7m by 2030 across the three major markets (*3MM). The major driver of this growth will be the launches of two novel symptomatic pipeline agents in this market, Neurocrine’s Ingrezza (valbenazine) and Prilenia’s Huntexil (pridopidine), says GlobalData, a leading data and analytics company.
The company’s report, ‘Huntington’s Disease: Opportunity Assessment and Forecast to 2030’, states that the HD market is currently dominated by generics and off-label drugs, with the exception of Teva’s Austedo (deutetrabenazine) that is only available in the US. This has resulted in limited treatment costs and market sales. Therefore, the introduction of two relatively expensive pipeline products into this stagnant market will have a significant impact.
Early-stage agents account for approximately 98.5% of the HD pipeline; limited activity is seen in Phase III trials, with only two drugs ─ Ingrezza and Huntexil ─ currently under development at that stage. This reflects the complex nature of bringing new drugs into this rare disease market.
Sarah Elsayed, Neurology Analyst at GlobalData, comments: “Although the main focus for research and development in the HD pipeline is disease modifying treatments (DMTs), the majority of them are still in early stages of development. There are currently no late-stage pipeline agents that possess any disease-modifying benefits, especially following the failure of Roche’s gene therapy, tominersen and Wave’s antisense oligonucleotides (ASO), rovanersen and lexanersen, in March 2021.
However, there are a few early-stage pipeline agents that hold some promise as potential DMTs including UniQure’s gene therapy AMT-130 and Wave’s ASO WVE-003, which are undergoing Phase Ib/IIa trials, thus they are not expected to enter the market before 2030.
Elsayed adds: “The HD therapeutics market is considerably sparse, and there are only two currently FDA-approved treatments for the symptomatic management of chorea associated with HD, Bausch’s Xenazine (tetrabenazine) and Teva’s Austedo. A large number of symptomatic treatments are currently used off-label for HD. The most frequently used drug classes are antipsychotics, antidepressants, anticonvulsants, benzodiazepines, botulinum toxins, and antiparkinsonian drugs. As such, significant clinical unmet needs remain in the HD space; namely the development of a DMT that can slow or halt the progression of the disease, improved symptomatic treatments with less adverse events, and effective treatments for cognitive impairment associated with HD.
Key opinion leaders (KOLs) interviewed by GlobalData noted that ongoing research is helping to further the understanding of the pathogenesis of HD and could lead to the identification of novel pharmaceutical targets. Therefore, a significant opportunity exists for drug developers to bring the first DMT to the market, where it is anticipated to receive strong patient uptake.”
* 3MM: The US, Germany, and the UK.